[1. UMANATH K., LEWIS JB., Update on Diabetic Nephropathy: Core Curriculum 2018, Am. J. Kidney. Dis., 2018, 71(6):884–895.]Search in Google Scholar
[2. PUGLIESE G., PENNO G., NATALI A., BARUTTA F., DI PAOLO S., REBOLDI G. et al., Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”, J. Nephrol., 2020, 33(1):9–35.]Search in Google Scholar
[3. PERSSON F., ROSSING P., Diagnosis of diabetic kidney disease: state of the art and future perspective, Kidney. Int. Suppl (2011), 2018, 8(1):2–7.]Search in Google Scholar
[4. UWAEZUOKE SN., The role of novel biomarkers in predicting diabetic nephropathy: a review, Int. J. Nephrol. Renovasc. Dis., 2017, 10:221–231.10.2147/IJNRD.S143186556636728860837]Search in Google Scholar
[5. LEE SY., CHOI ME., Urinary biomarkers for early diabetic nephropathy: beyond albuminuria, Pediatr. Nephrol., 2015, 30(7):1063–1075.]Search in Google Scholar
[6. DAI H., LIU Q., LIU B., Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy., J. Diabetes. Res., 2017, 2017:2615286.10.1155/2017/2615286553429428791309]Search in Google Scholar
[7. LIAPIS H., ROMAGNANI P., ANDERS HJ., New insights into the pathology of podocyte loss: mitotic catastrophe., Am. J. Pathol. 2013, 183(5):1364–1374.]Search in Google Scholar
[8. MATOVINOVIC MS., 3. Podocyte Injury in Glomerular Diseases., EJIFCC, 2009, 20(1):21–27.]Search in Google Scholar
[9. NAKAMURA T., USHIYAMA C., SUZUKI S., HARA M., SHIMADA N.,EBIHARA I. et al., Urinary excretion of podocytes in patients with diabetic nephropathy, Nephrol. Dial. Transplant., 2000, 15:1379–1383.10.1093/ndt/15.9.137910978394]Search in Google Scholar
[10. WEIL EJ., LEMLEY KV., MASON CC., YEE B., JONES LI., BLOUCH K. et al., Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy, Kidney. Int., 2012, 82(9):1010–1017.]Search in Google Scholar
[11. FISHEA T., Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients, Biomark. Res., 2015, 3:16.10.1186/s40364-015-0042-3449123926146561]Search in Google Scholar
[12. NAUTA FL., BOERTIEN WE., BAKKER SJL., GOOR HV., OEVEREN WV., YONG PE. et al., Glomerular and tubular damage markers are elevated in patients with diabetes, Diabetes. Care., 2011, 34:975–981.10.2337/dc10-1545306406021307379]Search in Google Scholar
[13. KANDASAMY Y., SMITH R., LUMBERS ER., RUDD D., Nephrin – a biomarker of early glomerular injury, Biomark. Res., 2014, 2:21.10.1186/2050-7771-2-21436319225789166]Search in Google Scholar
[14. SEKULIC M., SEKULIC PS., A compendium of urinary biomarkers indicative of glomerular podocytopathy, Pathol. Res. Int., 2013, 2013:782395.10.1155/2013/782395384533624327929]Search in Google Scholar
[15. GLUHOVSCHI C., GLUHOVSCHI G., PETRICA L., TIMAR R., VELCIOV S., IONITA I. et al., Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy, J. Diabetes. Res., 2016, 2016:4626125.10.1155/2016/4626125492799027413755]Search in Google Scholar
[16. REISER J., ALTINTAS MM., Podocytes, F1000Res, 2016, 5:F1000 Faculty Rev-114.10.12688/f1000research.7255.1475540126918173]Search in Google Scholar
[17. NIELSEN J., MCNAGNY K., The Role of Podocalyxin in Health and Disease, J. Am. Soc. Nephrol., 2009, 20(8):1669–1676.]Search in Google Scholar
[18. KOSTOVSKA I., TRAJKOVSKA TK., CEKOVSKA S., SPASOVSKI G., LABUDOVIC D., Nephrin and Podocalyxin – New Podocyte Proteins for Early Detection of Secondary Nephropathies, BANTAO J., 2016, 14(1):11–16.]Search in Google Scholar
[19. SUN D., ZHAO X., MENG L., Relationship between urinary podocytes and kidney diseases, Ren. Fail. 2012, 34(3):403–407.10.3109/0886022X.2011.64962722250862]Search in Google Scholar
[20. AGARWAL R., Diabetic nephropathy, proteinuria, and progression of CKD, Clin. J. Am. Soc. Nephrol., 2009, 4:1523–1528.10.2215/CJN.0201030919478099]Search in Google Scholar
[21. KDIGO., Chapter 1: Definition and classification of CKD, Kidney. Int. Suppl., 2013, 3:19.10.1038/kisup.2012.64408969325018975]Search in Google Scholar
[22. COCKROFT DW., GAULT MH., Prediction of creatinine clearance from serum creatinine, Nephron., 1976, 16:31–41.10.1159/0001805801244564]Search in Google Scholar
[23. NAVRA AS., BILOUS RW., Laboratory Assessment of Diabetic Kidney Disease, Diabetes. Spectr., 2015, 28(3):162–166.]Search in Google Scholar
[24. ŠIMUNDIC AM., Measures of Diagnostic Accuracy: Basic Definitions, EJIFCC., 2009, 19(4):203–211.]Search in Google Scholar
[25. HABIBZADEH F., HABIBZADEH P., YADOLLAHIE M., On determining the most appropriate test cut-off value: the case of tests with continuous results, Biochem. Med., 2016, 26(3):297–307.]Search in Google Scholar
[26. CHIDA S., FUJITA Y., OGAWA A., HAYASHI A., ICHIKAWA R., HAYASHI A. et al., Levels of albuminuria and risk of developing macroalbuminuria in type 2 diabetes: historical cohort study, Sci. Rep., 2016, 6:26380.10.1038/srep26380487647527210499]Search in Google Scholar
[27. El-SAEED GK., SHEHAB El-DEEN WA., MONTASR BA., OMAR TA., MOHAMED DS., Urinary podocalyxin and cyclophilin A: markers for early detection of type 2 diabetic nephropathy, Menoufia. Med. J., 2019, 32:996–1003.10.4103/mmj.mmj_223_18]Search in Google Scholar
[28. Al-RUBEAAN K., SIDDIQUI K., Al-GHONAIM MA., YOUSSEF AM., Al-SHARQAWI AH., AlNAQEB D., Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients, Sci. Rep., 2017, 7(1):2684.]Search in Google Scholar
[29. YE H., BAI X., GAO H., LI L., WU C., SUN X. et al., Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy, J. Diabetes. Complicat., 2014, 28:96–100.10.1016/j.jdiacomp.2013.08.00624075693]Search in Google Scholar
[30. HARA M., YAMAGATA K., TOMINO Y., SAITO A., HIRAYAMA Y., OGASAWARA S. et al., Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin, Diabetologia., 2012, 55(11):2913–2919.10.1007/s00125-012-2661-7346437122854890]Search in Google Scholar
[31. SHOJI M., KOBAYASHI K., TAKEMOTO M., SATO Y., YOKOTE K., Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabete, Biomarkers., 2016, 21(2):164–167.]Search in Google Scholar
[32. WANG R.,YAO C., LIU F., Association between Renal Podocalyxin Expression and Renal Dysfunction in Patients with Diabetic Nephropathy: A Single-Center, Retrospective Case-Control Study, BioMed. Res. Int., 2020, Article ID 7350781.10.1155/2020/7350781715779032337271]Search in Google Scholar
[33. BACCI MR., CHEHTER EZ., AZZALIS LA, COSTA DE AGUIAR ALVES B., FONCESKA FLA., Serum NGAL and Cystatin C Comparison With Urinary Albumin-to-Creatinine Ratio and Inflammatory Biomarkers as Early Predictors of Renal Dysfunction in Patients With Type 2 Diabetes, Kidney. Int. Rep., 2016, 2(2):152–158.]Search in Google Scholar